GenScript ProBio, a leading Biologics CDMO to the bio-pharmaceutical market, and mAbsolve, developers of a novel Fc silencing variant, announced a licensing deal for mAbsolve’s Fc silencing technology. The agreement provides GenScript ProBio with access to the new STR Fc silencing platform. The agreement provides GenScript ProBio’s clients with easy license-free access to the new STR Fc silencing platform for antibody research and development.
Fc-mediated immune effector activities are an important part of an antibody’s natural function, but in many therapeutic antibodies these interactions are not desirable and can lead to catastrophic side effects. Many approaches to eliminate effector function have been developed, but none completely silence the unwanted binding to Fc gamma receptors. The new STR Fc silencing platform, developed by mAbsolve and described in a recent PLOS One article, delivers the only truly silent Fc mutations described to date. The technology therefore has the potential to improve the safety and efficacy of therapeutic antibodies and Fc fusion proteins.
The license agreement allows GenScript ProBio to make this best-in-class Fc silencing technology available for GenScript ProBio’s biologics discovery projects and ensures its clients have the best possible starting position for further development of their lead antibody candidates.
“GenScript ProBio has a deep accumulation in the discovery and development of antibody drugs, and we are committed to accelerating drug research and development and improving quality of products,” said Dr. Brian Min, CEO of GenScript ProBio. “We are excited to partner with the mAbsolve team, who have a wealth of knowledge and experience in developing therapeutic antibodies, their novel Fc silencing technology will enhance drug efficacy for our clients.”
“mAbsolve is committed to improving the safety and effectiveness of therapeutic antibodies, and we strongly believe that STR technology can be of real benefit to the majority of antibody and Fc fusion proteins in development,” said Dr. Geoff Hale, Chief Executive Officer at mAbsolve. “Our STR mutations provide a truly silent and highly developable antibody Fc region, and we are eager to widely license it to partners such as GenScript ProBio, to make the technology easily accessible for therapeutic developers around the world.”
For more information, visit the GenScript ProBio or mAbsolve websites.
GenScript ProBio, a subsidiary of GenScript Biotech Corporation, offers end-to-end CDMO services from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in CGT, vaccine, biologics discovery and antibody protein drug, aiming to accelerate drug development for customers. GenScript ProBio has established companies in the United States, the Netherlands, South Korea, and China (Hong Kong, Shanghai, and Nanjing) and other regions to serve global customers, and has helped customers in the United States, Europe, Asia Pacific and other regions obtain more than 40 IND approvals since October 2017.
Toward the mission of “Innovation through Collaboration”, GenScript ProBio is committed to helping customers shorten the timeline for the development of biological drugs from discovery to commercialization, significantly lowering R&D costs and shaping a healthier future.
mAbsolve founded in the UK by pioneers of therapeutic antibody development and engineering from both Oxford and Cambridge. We have experienced the clinical challenges caused by incomplete silencing of antibodies using LALA, aglycosylated or IgG4 variants. To address this we have developed a best-in-class solution for silencing of antibody effector function. Our STR technology is the only truly silent Fc. Visit www.mabsolve.com for more information.